According to the instructions for medical use, the duration of the course depends on the form and severity of the disease, the prevalence of the process, options for the clinical course and are determined by the attending physician.
In order to fully disclose the therapeutic potential of the drug Mexidol ®, it is consistent long -term therapy (randomized clinical examination of Epica 1 , 2017): first 14 days of injection (saturation phase), with the subsequent transition to a tablet form of Mexidol ® or Mexol ® 250 V. the course of 2 months (phase of maximization of the therapeutic effect). The frequency of therapy is 2-3 times a year or during periods of exacerbations.
The effectiveness of consistent long -term therapy by Mexidol was confirmed in a recent study by E. Chukanova. (2019 2 ) In terms of efficiency and safety of consistent long-term therapy in patients with chemicals: a reliable improvement of cognitive functions (+3.3 points on the Mosa scale), reliable regression of asthenic symptoms (-32% on the asthenia scale of MFI-20), reliable Improving motor activity (+49% on the Tinetti scale), a reliable improvement in the emotional background on the HADS scale (-38% on an alarm scale and -29% on the depression scale), reliable regression of subjective neurological symptoms on the OSNS scale, also according to the results of the study High safety profile of this therapy.
Thus, it is necessary to adhere to the principle of consistent long -term therapy to achieve the maximum effect.
According to the instructions for the medical use of the drug Mexidol ® (solution), one of the recommended methods of administration is an intramuscular injection, which, with proper preparation, can be carried out at home 3 .
1 The results of the randomized, double-blind, multicenter, placebo-controlled, parallel-group study of the efficacy and safety of Mexidol® during long-term sequential therapy in patients with hemispheric ischemic stroke in the acute and early recovery periods (EPICA) were published in the S.S. Korsakov Journal of Neurology and Psychiatry in issue "Stroke" No. 3, 2017; Vol. 2, the leading VAK (Higher Attestation Commission) peer-reviewed publication for neurologists and psychiatrists in Russia. Learn more.
2 "Efficacy and Safety of Mexidol FORTE 250 as Part of Sequential Therapy in Patients with Chronic Cerebral Ischemia," E.I. Chukanova, A.S. Chukanova, S.S. Korsakov Journal of Neurology and Psychiatry, No. 9, 2019. Read more.
3 On the Neuroreab.ru there is an extremely important memo for the patient - step -by -step instructions for intramuscular injection, consisting of four simple steps and illustrated by visual pictures. Intramuscular injection at home is a convenient alternative for a patient who does not have the opportunity to visit hospital institutions. Watch the memo.